This is the text extract for 2012-03 Schedule Dispatch, browse documents here.

16 February 2012 March 2012 Pharmaceutical Schedule Dispatch This document is provided to pharmacists as an early notification of the changes to be announced in the March 2012 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details. New listings             Adrenaline (Aspen Adrenaline) inj 1 in 10,000, 10 ml (p’code 2390949) Amoxycillin clavulanate (Curam Duo) tab amoxycillin 500 mg with potassium clavulanate 125 mg – up to 30 tab available on a PSO (p’code 2396629) Clindamycin (Clindamycin ABM) cap hydrochloride 150 mg – maximum of 4 cap per prescription; can be waived by endorsement – Retail pharmacy – Specialist (p’code 2397501) Gemcitabine hydrochloride (Gemcitabine Actavis s29) inj 200 mg (p’code 2398915) and 1 g (p’code 2398907) – PCT only – Specialist – Special Authority Octreotide (somatostatin analogue) (Octreotide MaxRx) inj 50 µg per ml, 1 ml (p’code 2396939) 100 µg per ml, 1 ml (p’code 2396947) and 500 µg per ml, 1 ml (p’code 2396955) ) – Special Authority – Retail Pharmacy Pharmacy Services (BSF Lostaar) brand switch fee (p’code 2397145) Pharmacy Services (BSF Arrow-Losartan & Hydrochlorothiazide) brand switch fee (p’code 2397153) Rizatriptan (Rizamelt) tab orodispersible 10 mg (p’code 2394634) Tetrabenazine (Motetis) tab 25 mg (p’code 2394383) Thiotepa (THIO-TEPA s29) inj 15 mg (p’code 256811) – PCT only – Specialist Ursodeoxycholic acid (Ursosan) cap 250 mg (p’code 2397528) – Special Authority – Retail Pharmacy Zinc and castor oil (Multichem) oint 500 g (p’code 544345)

Changes to restrictions  Losartan (Lostaar) tab 12.5 mg, 25 mg, 50 mg and 100 mg – brand switch fee  Losartan with hydrochlorothiazide (Arrow-Losartan & Hydrochlorothiazide) tab 50 mg with hydrochlorothiazide 12.5 mg– brand switch fee  Propranolol (Cardinol) tab 10 mg and 40 mg – removal of stat. Stat remains on propranolol (Cardinol LA) tab 160 mg  Rizatriptan – amended presentation description from rizatriptan benzoate wafer to rizatriptan orodispersible tab  Zoledronic acid – amended Special Authority criteria  Ursodeoxycholic acid – amended Special Authority criteria Decreased subsidy

Chemical Presentation Fully subsidised brands Partially subsidised brands Apo-Clarithromycin Klamycin Nitrolingual Pumpspray Glytrin* AFT*

Clarithromycin Glyceryl trinitrate

Tab 500 mg Oral pump spray 400 µg per dose

Cefazolin sodium A483831 - qA22813

Inj 500 mg

Hospira

Inj 1 g Cefuroxime sodium Tetrabenazine Temozolomide Inj 750 mg Tab 25 mg Cap 5 mg Cap 20 mg Cap 100 mg Cap 250 mg * Note - there is no subsidy change for this brand.

AFT* m-Cefuroxime* Xenazine 25 Motetis* Temodal Temaccord* Temodal Temaccord* Temodal Temaccord* Temodal Temaccord*

Hospira Zinacef

Increased subsidy Chemical

Orphenadrine Hydrochloride

Presentation

Tab 50 mg

Fully subsidised brands

Disipal

NB. For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: www.pharmac.govt.nz/healthpros/Schedule.

A483831 - qA22813